Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial. (2022)
Attributed to:
CATALYST a randomised early phase adaptive trial for new drugs for SARS-CoV-2+ patients
funded by
COVID
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s2213-2600(21)00460-4
PubMed Identifier: 34922649
Publication URI: http://europepmc.org/abstract/MED/34922649
Type: Journal Article/Review
Volume: 10
Parent Publication: The Lancet. Respiratory medicine
Issue: 3
ISSN: 2213-2600